Dietary Sources of Lysophospholipids

Obesity Clinical Trial

Official title:

Dietary Sources of Lysophospholipids

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02952638
• Other study ID #: 14-1001-FIV
• Status: Terminated
• Start date: July 14, 2015
• Est. completion date: December 2015

Study information

• Verified date: July 2021
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to test the hypothesis that dietary intake of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) acutely alters plasma lysophosphatidic acid (LPA) levels and autotaxin activity in normal weight and obese subjects.

Description:

Lysophosphatidic acid (LPA) is a simple glycerophospholipid that is found at biologically-relevant levels in plasma and has important effects on isolated or cultured blood, vascular and fat cells. The main enzyme responsible for generation of plasma LPA is the secreted lysophospholipase D, autotaxin (ATX). Adipocytes contribute substantially to plasma ATX levels. The investigators have demonstrated rapid production and metabolism of plasma LPA in animals. More recently, the investigators have observed that plasma LPA levels increase in mice fed a high fat ("Western") diet in comparison to levels found in mice fed normal chow. The investigators have also found that diet-induced obesity increased circulating ATX levels in mice. The investigators hypothesize that diet, and in particular dietary phosphatidylcholine (PC), may regulate the autotaxin substrate lysophosphatidylcholine (LPC), from which LPA is derived. Obesity may amplify the response by increasing plasma ATX levels and/or activity. The current study will test whether dietary PC in normal weight and obese subjects acutely alters LPA levels and autotaxin activity.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 44
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 18 to 60 years old
• Body Mass Index of 20 and above
• Must be able to consume a low fat meal, unlimited fruits and vegetables and not eating after midnight the night before the lipid tolerance test
• Report to the clinical research unit fasting (no food since the meal the night before)
• Able to consume a liquid meal consisting of a commercial nutritional product supplemented with fat
• Able to have an indwelling catheter placed on one arm and have hourly blood draws for 8 hours

Exclusion Criteria:

• Unstable medical condition (recent or unstable cardiovascular disease)
• Active cancer
• Renal insufficiency Glomerular Filtration Rate <30
• Use of steroids
• Chronic inflammatory conditions
• Use of anticoagulants, anti-inflammatory, or lipid-lowering medications
• Lipodystrophy
• GI conditions that result in lipid intolerance
• Pregnant women have a tendency to be anemic and therefore will be excluded.

Related Conditions & MeSH terms

• Cardiovascular Risk Factor
• Hyperlipidemia
• Hyperlipidemias
• Obesity

Locations

Country	Name	City	State
United States	University of Kentucky Dept of Cardiology	Lexington	Kentucky

Sponsors (1)

Lead Sponsor	Collaborator
Susan Smyth

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma Autotaxin-dependent formation of Lysophosphatidic acid, and Levels of Phosphatidylcholine and its metabolites - Lysophosphatidylcholine, Lysophosphatidic acid, Choline, Trimethylamine and Trimethylamine oxide measured by Tandem Mass Spectrometry	Investigators will use tandem mass spectrometry to measure the most abundant metabolite species. Enzymatic activity of autotaxin involves incubation with the substrate lysophosphatidylcholine and monitoring concentration dependent release of lysophosphatidic acid. Levels of Lysophospholipids Phosphatidylcholine and the products of its metabolism in the blood will be measured. Quantitation will be achieved by stable isotope dilution and by reference to offline calibration curves. By using mass spectrometry and metabolic tracers, studies using a common protocol are effectively multiplexed so data on both endogenous and mass labeled lipids can be obtained from a single individual. Given the sensitivity of these analytical methods (limits of quantitation of approximately 1 fmol), the measurements and the quantities will be reported as concentration in picomoles per liter of plasma volume. A statistical correlation with each group based on BMI will be performed.	8 hours